Trials / Withdrawn
WithdrawnNCT02011594
Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is advantageous for advanced esophageal cancer patients in combination with chemotherapy or radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to advanced esophageal cancer patients is not known.
Detailed description
We design this clinical trial to confirm the efficacy of maintenance treatment of nimotuzumab after initial treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nimotuzumab | 400mg Q2W intravenously |
| DRUG | Placebo | Normal saline |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-01-01
- Completion
- 2015-02-01
- First posted
- 2013-12-13
- Last updated
- 2015-02-12
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02011594. Inclusion in this directory is not an endorsement.